Phase 2Recruiting

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (ATUNE)

Sponsor
University of North Carolina, Chapel Hill (Academic or other)
Enrollment
52 planned
Conditions
EoE; Eosinophilic Esophagitis; Eosinophilic Esophagitis (EoE)
Interventions
Upadacitinib 30mg Dose; Upadacitinib Matching Placebo
Ages
adults, older adults
Registry
NCT07588568

Full record on ClinicalTrials.gov

From the registry

The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests

Primary outcomes

  • Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatment

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered